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OBJECTIVE — ToinvestigatetheeffectsoffenoﬁbrateandcoenzymeQ10(CoQ)ondiastolic
function, ambulatory blood pressure (ABP), and heart rate (HR) in type 2 diabetic subjects with
left ventricular diastolic dysfunction (LVDD).
RESEARCH DESIGN AND METHODS — We randomized, double-blind, 74 subjects
to fenoﬁbrate 160 mg daily, CoQ 200 mg daily, fenoﬁbrate 160 mg plus CoQ 200 mg daily, or
matchingplacebofor6months.Echocardiography(includingtissueDopplerimaging)and24-h
ABP and HR monitoring were performed pre- and postintervention.
RESULTS — Neither fenoﬁbrate nor CoQ, alone or in combination, altered early diastolic
mitralannularmyocardialrelaxationvelocity(E),early-to-latemitralinﬂowvelocityratio(E/A),
deceleration time, isovolumic relaxation time, or the ratio of early mitral ﬂow velocity to early
diastolicmitralannularmyocardialrelaxationvelocity(E/E)comparedwithplacebo(P0.05).
Fenoﬁbrate and CoQ interactively (P  0.001) lowered 24-h systolic blood pressure (3.4 
0.09 mmHg, P  0.010), with a prominent nocturnal effect (5.7  1.5 mmHg, P  0.006).
Fenoﬁbrate (1.3  0.5 mmHg, P  0.013) and CoQ (2.2  0.5 mmHg, P  0.001)
independentlylowered24-hdiastolicbloodpressure.Fenoﬁbratereduced24-hHR(3.30.5
beats/min, P  0.001), but CoQ had no effect on HR.
CONCLUSIONS — In type 2 diabetic subjects with LVDD, neither fenoﬁbrate nor CoQ,
alone or in combination, improved diastolic function signiﬁcantly. However, fenoﬁbrate and
CoQ independently and interactively lowered 24-h blood pressure, and fenoﬁbrate alone re-
duced 24-h HR.
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T
heincreasedriskofcardiacfailurein
diabetes reﬂects not only coexistent
coronary artery disease and hyper-
tension, but also a speciﬁc diabetic car-
diomyopathy (DCM) (1). Multiple
mechanisms underlie DCM, including al-
tered substrate utilization and energetics,
oxidative stress, endothelial dysfunction,
myocardialﬁbrosis,andmyocyteapopto-
sis. DCM can manifest as impaired relax-
ation and increased stiffness of the
myocardium (2), detectable preclinically
by echocardiography as left ventricular
diastolic dysfunction (LVDD). Therapies
targetinghypertension,dyslipidemia,and
hyperglycemia, as well as the speciﬁc
mechanisms underlying DCM, may pre-
ventprogressionofLVDDtoovertcardiac
failure.
Fenoﬁbrate,aperoxisomeprolifera-
tor–activated receptor (PPAR)- ago-
nist, lowers triglycerides and raises
HDL cholesterol. It could improve
LVDD in diabetes by reducing myocar-
dial free fatty acid and triglyceride de-
livery, thereby decreasing formation of
lipid intermediates and oxidant species
that promote myocyte apoptosis and ﬁ-
brosis (1). However, in experimental
animal models, PPAR- overstimula-
tion can promote fatty acid oxidation,
leading to inefﬁcient myocardial bioen-
ergetics and pathologic remodeling (3).
Importantly, there is no evidence for
this in humans treated with ﬁbrates (4),
and in clinical trials in type 2 diabetes,
fenoﬁbrate reduced angiographic pro-
gression of coronary atherosclerosis (5)
and microangiopathy (6), improved en-
dothelial dysfunction (7), and modestly
lowered blood pressure (BP) (6). De-
spite these effects, fenoﬁbrate did not
signiﬁcantly decrease coronary events,
the primary end point, in the Fenoﬁ-
brate Intervention and Event Lowering
inDiabetes(FIELD)study(6),butitdid
reduce total cardiovascular events.
CoenzymeQ10(CoQ),akeyinterme-
diaryinmitochondrialelectrontransport,
has potent antioxidant properties. CoQ
supplementation could improve LVDD
by increasing myocardial energy produc-
tion and decreasing oxidative stress, ac-
tions complementary to fenoﬁbrate. CoQ
improves endothelial function in type 2
diabetes (8), with modest beneﬁcial ef-
fects on BP (9) and left ventricular (LV)
systolic function (10).
We previously showed that fenoﬁ-
brate and CoQ synergistically improve
microcirculatory function in type 2 di-
abetes (11). By targeting several mech-
anisms underlying LVDD in type 2
diabetes, we hypothesized that these
treatments would improve cardiac
function.AlthoughfenoﬁbrateandCoQ
may lower clinic blood pressure (CBP),
their effect on diurnal BP has not been
investigated. Our secondary hypothesis
was that these treatments would inde-
pendently and interactively lower am-
bulatory blood pressure (ABP) and, by
improving cardiac function, also lower
heart rate (HR).
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Subjects
We studied 74 type 2 diabetic subjects,
aged 40 to 79 years, who had LVDD on
echocardiography. All were recruited
from clinical databases at teaching hospi-
tals in Perth, Western Australia. Type 2
diabetes was deﬁned by American Diabe-
tes Association criteria. Exclusions in-
cluded daytime insulin use, GHb 9.0%,
resting BP 150/90 mmHg, fasting cho-
lesterol 7.0 mmol/l, triglycerides 4.0
mmol/l, creatinine 130 mol/l, treat-
ment with ﬁbrates or CoQ 30 mg/day,
and any cardiovascular event within the
preceding 6 months. The study was ap-
proved by the ethics committees of Royal
Perth, Fremantle, and Sir Charles Gaird-
ner Hospitals. All participants gave in-
formed written consent.
Study design
Subjects were randomized, double-blind,
to fenoﬁbrate 160 mg daily (Laboratoires
Fournier,Chenove,France),CoQ200mg
daily (RP Scherer, Braeside, Australia), fe-
noﬁbrate160mgplusCoQ200mgdaily,
or matching placebo for 6 months. These
doses and this duration of therapy were
equivalent to those employed in previous
clinical studies of these compounds
(7,8,11). Participants underwent two
echocardiograms at baseline and two at
treatment end, with pre- and postinter-
vention data taken as the mean value at
eachtimepoint.Theprimaryechocardio-
graphic end point was early diastolic sep-
tal mitral annular myocardial relaxation
velocity (E), a tissue Doppler index of
diastolic function. In this factorial design,
a sample size of 15 subjects per treatment
group was required to detect main treat-
ment effects of 10% change in E com-
pared with placebo at 0.05 and 80%
power. Secondary end points included
other diastolic and systolic function in-
dexes, left atrial volume (LAV), and LV
mass(LVM).ABPandHRweremonitored
over 24 h at baseline and treatment end.
Fasting venous samples were drawn at
baseline and treatment end to measure
lipids, apolipoproteins, glucose, GHb,
and CoQ. Creatinine, hepatic transami-
nases, and creatine kinase were moni-
tored periodically throughout the study.
Echocardiography
Transthoracic echocardiography was per-
formed at rest. Mitral annular tissue
Doppler, transmitral and pulmonary ve-
nous (PV) ﬂow, and color M-mode ﬂow
propagation (Vp) were measured in the
apical four-chamber view. LV end-
diastolic and end-systolic volumes were
estimated in the apical two-chamber view
(Simpson’s biplane method) to calculate
LV ejection fraction (LVEF). Data were
taken as the mean of three measurements
on different cardiac cycles. Exclusions
included LVEF 50%, wall motion ab-
normalities, valvular disease, atrial ﬁbril-
lation, frequent ectopy, paced rhythm,
andearly-to-latemitralinﬂowvelocityra-
tio (E/A) wave fusion. One echocardiog-
rapher, blinded to treatment allocation,
performed all studies.
LVDD classiﬁcation
LVDD was classiﬁed using age-speciﬁc
modiﬁcations of the Canadian Consensus
(12) and Garcia (13) criteria. Participants
were classiﬁed as having mild LVDD if
three or more of the following criteria
weremet,includingatleastoneoftheﬁrst
two: reduced E/A (age 40–49 years:
1.3; 50–59 years: 1.2; 60–69 years:
1.1; 70–79 years: 0.8), increased de-
celeration time (DT) (40–59 years: 200
ms;60–69years:220ms;70–79years:
250 ms), isovolumic relaxation time
(IVRT) 100 ms, reduced E (40–59
years: 10.0 cm/s; 60–79 years: 8.0
cm/s), and Vp 45.0 cm/s. Participants
were classiﬁed as having moderate LVDD
if the ratio of early mitral ﬂow velocity to
early diastolic mitral annular myocardial
relaxation velocity (E/E) 8.0 and three
ormoreofthefollowingweremet:40%
decrease in E/A with Valsalva maneuver,
E/Vp 1.50, systolic-to-diastolic PV ﬂow
velocity ratio (PV S/D) 1.00, atrial sys-
tolic PV reversal ﬂow velocity (PV ‘a’ rev)
0.35 m/s, normal E/A, and normal DT.
Ambulatory monitoring
ABP and HR were measured every 20 min
during daytime (0900–2100) and every
30 min at night (2100–0900) using an
Ultralite 90217 Monitor (Spacelabs Med-
ical, Issaquah, WA). Participants re-
corded sleeping and waking times during
monitoring. Datasets with 80% valid
readings were excluded from analysis.
Laboratory analyses
Cholesterol, triglycerides, and HDL cho-
lesterol were measured by enzymatic
methods (Hitachi, Tokyo, Japan; Roche
Diagnostics, Mannheim, Germany), and
LDL cholesterol was calculated. Apoli-
poproteins (apos) A-I, A-II, and B-100
were measured by immunonephelometry
(Dade-Behring BNII, Marburg, Germany)
and C-III by immunoturbimetry (Wako
Pure Chemical Industries, Osaka, Japan).
Nonesteriﬁed fatty acids (NEFAs) were
measured by enzymatic methods (Wako
Pure Chemical Industries), plasma CoQ
by reverse-phase high-performance liq-
uid chromatography using electrochemi-
cal detection, and cellular CoQ by high-
performance liquid chromatography
using isolated peripheral blood mononu-
clear cells with correction for protein
content.
Statistical analyses
DatawereanalyzedusingSPSS12.0(Chi-
cago, IL) and SAS 9.1 (Cary, NC). Values
are presented as means  SEM unless
otherwise indicated. Skewed data were
logarithmically transformed. Only sub-
jects who completed the study were in-
cluded in efﬁcacy analyses. Main
treatment effects on echocardiographic
and biochemical indexes were assessed
using general linear modeling with ad-
justment for baseline and study site. For
ABP and HR, main treatment effects were
assessed using mixed models (study sub-
ject as random effect) adjusted for base-
line, study site, hour, weight change, and
antihypertensive use. Where signiﬁcant
treatment interaction was found, analyses
bytreatmentgroupwereundertakenwith
Scheffe adjustment for multiple compari-
sons.Pvalues0.05wereconsideredsta-
tistically signiﬁcant.
RESULTS
Baseline characteristics
We randomized 74 eligible subjects to
placebo (n  20), fenoﬁbrate (n  19),
CoQ(n16),orfenoﬁbrate	CoQ(n
19). Clinical characteristics were compa-
rable across treatment groups (Table 1).
Participants were typically overweight
with satisfactory control of BP, lipids, and
glycemia.Mediandiabetesdurationwas4
years;one-thirdofcaseswerediettreated.
Nearly one-half of subjects were taking
antihypertensive medication, most com-
monlyACEinhibitors;overone-halfwere
taking statins. On echocardiography, 12
participants(16.2%)hadLVhypertrophy
(LVM/height 143 g/m for men; 102
g/m for women). Most subjects (86.5%)
had mild LVDD.
Clinical and biochemical responses
A total of 69 subjects completed the trial.
Reasons for withdrawal were new-onset
atrialﬁbrillation(n1),transaminaseel-
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limit of normal (n  1), and personal
choice (n  3). The subjects with adverse
events were on fenoﬁbrate alone.
Compared with placebo, neither
body weight (data not shown) nor glyce-
mia changed with any of the treatments
(Table 2). Total, HDL, and LDL choles-
terolandNEFAsweresimilarlyunaltered,
but fenoﬁbrate lowered triglycerides,
apoB-100, and apoC-III and increased
apoA-IandapoA-II(P0.05).CoQsup-
plementation increased both plasma and
cellular CoQ levels (P  0.01).
Echocardiographic indexes
Compared with placebo, none of the
treatments signiﬁcantly altered the pri-
mary end point (E) or any of the follow-
ing diastolic function indexes: E/A, DT,
IVRT,PVS/D,orE/E(Table3).However,
fenoﬁbrate increased Vp (2.4  1.0 cm/s,
P  0.020), and CoQ increased E/Vp
(0.12  0.05, P  0.007) and PV ‘a’ rev
(0.02  0.01m/s, P  0.009). In most
subjects (82.6%), LVDD classiﬁcation
was unchanged by treatment: one subject
each in the fenoﬁbrate and fenoﬁbrate 	
CoQ groups progressed from mild to
moderate LVDD, whereas LVDD im-
proved in four subjects taking placebo,
three taking fenoﬁbrate, two taking CoQ,
and one taking fenoﬁbrate 	 CoQ. None
of the treatments signiﬁcantly altered sys-
tolic function (systolic myocardial con-
traction velocity [S and LVEF) or cardiac
structure(LAVandLVM).Adjustmentfor
statin use did not alter these ﬁndings.
ABP and HR
Of those who completed the study, eight
subjects declined ambulatory monitoring
and seven had insufﬁcient readings. Fe-
noﬁbrate and CoQ synergistically (P 
0.001)lowered24-hsystolicBP(SBP)(fe-
noﬁbrate 	 CoQ: 3.4  0.9 mmHg,
P  0.010; fenoﬁbrate: 1.8  1.0 mmHg,
P0.341;CoQ:0.31.1mmHg,P
0.992; all P vs. placebo), particularly dur-
ingsleep(fenoﬁbrate	CoQ:5.71.5
mmHg, P  0.006; fenoﬁbrate: 0.2 
1.5 mmHg, P  0.999; CoQ: 2.2  1.7
mmHg, P  0.647; all P vs. placebo) (Ta-
ble 4). Fenoﬁbrate (1.3  0.5 mmHg,
P0.013)andCoQ(2.20.5mmHg,
P  0.001) had independent effects in
lowering 24-h diastolic BP (DBP): fenoﬁ-
brate lowered asleep DBP (2.6  0.9,
P  0.005), whereas CoQ lowered awake
DBP (2.7  0.6, P  0.001). Fenoﬁ-
brate also decreased 24-h HR (3.3 
0.5 beats/min, P  0.001), observed dur-
ing both waking and sleeping (P 
0.001). CoQ supplementation did not al-
ter HR. Adjustment for statin use did not
alter these ﬁndings.
CONCLUSIONS — In type 2 dia-
beticsubjectswithLVDD,fenoﬁbrateand
CoQ, alone or in combination, did not
signiﬁcantly alter LV function. However,
we provide new evidence that these treat-
ments have independent and interactive
effects in lowering ABP, with fenoﬁbrate
alone also decreasing HR.
Table 1—Baseline characteristics of randomized subjects
Placebo Fenoﬁbrate CoQ Combination
n 20 19 16 19
Age (years) 62.4  8.8 64.8  7.3 61.3  4.1 63.0  9.4
Male/female (n) 14/6 13/6 13/3 13/6
BMI (kg/m
2) 30.7  5.0 29.9  5.6 30.1  4.6 28.7  3.4
Fasting glucose (mmol/l) 7.2  1.8 7.0  1.1 7.6  1.6 7.6  2.2
GHb (%) 6.5  1.0 6.5  0.9 6.6  0.9 6.6  0.8
Duration of type 2 diabetes (years) 5.5 (4.1–7.5) 4.5 (2.7–7.5) 3.1 (1.8–5.4) 3.0 (2.0–4.9)
Resting SBP (mmHg) 130.5  15.7 131.0  17.8 136.8  14.7 132.8  17.3
Resting DBP (mmHg) 73.0  11.8 73.3  10.4 76.9  10.0 74.1  9.2
Total cholesterol (mmol/l) 4.4  1.2 4.6  0.9 4.6  0.9 4.6  0.8
Triglycerides (mmol/l) 1.6  0.7 1.6  1.0 1.7  0.7 1.7  0.8
HDL cholesterol (mmol/l) 1.22  0.27 1.29  0.36 1.25  0.25 1.35  0.38
LDL cholesterol (mmol/l) 2.5  1.1 2.6  0.7 2.6  0.8 2.5  0.7
Serum creatinine (umol/l) 82  16 74  10 79  15 75  15
History of ischemic heart disease 15.0 15.8 12.5 10.5
LV hypertrophy 20.0 26.3 6.3 10.5
LVDD: mild/moderate (n) 16/4 17/2 15/1 16/3
Medications
No antihyperglycemic medication 25.0 42.1 43.8 26.3
Metformin 60.0 47.4 50.0 68.4
Sulphonylurea 50.0 42.1 37.5 21.1
Nocturnal basal insulin 5.0 10.5 6.3 0.0
No antihypertensive medication 35.0 63.2 50.0 63.2
ACE inhibitor 45.0 26.3 37.5 15.8
Angiotensin receptor blocker 15.0 10.5 6.3 5.3

-Adrenergic receptor blocker 5.0 5.3 25.0 10.5
Calcium channel blocker 25.0 15.8 18.8 10.5
Diuretic 30.0 10.5 18.8 10.5
Statin 75.0 36.8 68.8 52.6
Data are means  SD, percent, or geometric means (95% CI).
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LVDD is common in diabetes and is asso-
ciated with increased mortality (14).
However, few studies have investigated
potentialtherapies.Intype2diabeticsub-
jects with LVDD, 6 months’ treatment
with candesartan improved one index of
diastolic ﬁlling (E/A), but not another
(DT) (15). In hypertensive patients with
LVDD, 12% of whom had diabetes, BP
reduction over 38 weeks improved myo-
cardial relaxation (E) irrespective of the
agent used, but the independent effect of
diabetes was not assessed (16). No trials
have previously examined fenoﬁbrate’s
effect on cardiac failure or LVDD. Small
trials in heart failure patients collectively
suggest a modest beneﬁt of CoQ on sys-
tolic function (10), but no studies have
investigated its effect on LVDD.
Intype2diabetes,LVDDisassociated
with abnormal high-energy phosphate
metabolism (17), and we anticipated that
fenoﬁbrate and CoQ would improve
LVDD in type 2 diabetes by reducing li-
potoxicity and oxidative stress and im-
proving endothelial function and
myocellular energetics. However, we did
not demonstrate treatment effects on
myocardial relaxation (E) or several
other diastolic function indexes, suggest-
ing that possible favorable effects of feno-
ﬁbrate could have been offset by adverse
consequences of PPAR- stimulation on
myocardial fatty acid oxidation and ener-
getics (3). Our study was powered to de-
tect clinically relevant main treatment
effects of 10% change in E compared
with placebo. We observed statistically
signiﬁcantmixedtreatmenteffectsonsev-
eral secondary diastolic indexes, such as
increase in Vp (potentially beneﬁcial),
Table 3—Effect of interventions on echocardiographic indices
Placebo Fenoﬁbrate CoQ Combination
P for
interaction
Fenoﬁbrate
main effect P
CoQ main
effect P
n 20 16 16 17
E (cm/s)
Baseline 8.4  0.3 8.5  0.3 9.2  0.4 8.6  0.4
End 8.6  0.3 8.1  0.3 8.9  0.4 8.7  0.4 0.094 0.1  0.2 0.539 0.1  0.2 0.698
E/A
Baseline 0.82  0.03 0.83  0.03 0.90  0.04 0.91  0.10
End 0.83  0.03 0.85  0.03 0.92  0.04 0.99  0.11 0.262 0.04  0.02 0.112 0.04  0.02 0.129
DT (ms)
Baseline 218  6 233  7 215  8 215  7
End 215  6 220  9 206  7 212  6 0.376 2  6 0.779 2  6 0.737
IVRT (ms)
Baseline 106  3 108  1 108  2 109  2
End 108  2 112  3 109  3 111  2 0.655 2  2 0.338 1  2 0.530
Vp (cm/s)
Baseline 41.5  1.4 42.0  1.3 44.1  2.0 41.9  1.7
End 40.9  1.2 44.4  1.8 42.9  1.7 42.9  1.9 0.531 2.4  1.0 0.020 0.8  1.0 0.451
E/E
Baseline 7.7  0.3 8.0  0.4 7.8  0.5 7.9  0.5
End 7.6  0.3 8.5  0.3 8.3  0.5 8.6  0.5 0.345 0.5  0.3 0.078 0.4  0.3 0.130
E/Vp
Baseline 1.56  0.07 1.60  0.06 1.59  0.05 1.60  0.08
End 1.59  0.06 1.56  0.05 1.70  0.07 1.73  0.07 0.367 0.00  0.05 0.940 0.12  0.05 0.007
PV S/D
Baseline 1.55  0.06 1.50  0.06 1.41  0.09 1.61  0.13
End 1.60  0.06 1.52  0.07 1.43  0.09 1.43  0.08 0.933 0.06  0.07 0.390 0.12  0.07 0.081
PV ‘a’ rev (m/s)
Baseline 0.33  0.01 0.33  0.01 0.31  0.01 0.33  0.01
End 0.32  0.01 0.32  0.01 0.33  0.01 0.34  0.01 0.785 0.00  0.01 0.457 0.02  0.01 0.009
LVEF (%)
Baseline 63.2  0.9 61.6  1.0 64.6  0.9 63.3  1.2
End 64.1  0.8 62.6  1.2 64.6  1.1 62.4  0.8 0.615 0.0  0.8 0.961 1.3  0.8 0.102
S (cm/s)
Baseline 8.8  0.2 9.4  0.3 9.4  0.3 8.7  0.3
End 9.1  0.2 9.3  0.4 9.8  0.4 8.6  0.3 0.417 0.5  0.3 0.071 0.0  0.3 0.914
LAV/BSA (ml/m
2)
Baseline 30.4  1.3 32.4  1.8 31.3  1.8 35.9  2.5
End 32.4  1.5 33.9  1.8 31.7  1.5 36.4  2.6 0.649 0.4  1.0 0.693 1.0  1.0 0.335
LVM/BSA (g/m
2)
Baseline 92.5  3.8 101.5  4.2 94.8  3.5 90.1  3.8
End 95.0  4.0 106.3  4.5 95.1  3.1 91.2  4.2 0.533 2.4  1.8 0.195 3.5  1.8 0.059
Data are means  SEM. Main effect vs. placebo, adjusted for baseline and study site (general linear model). BSA, body surface area.
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but these were small (10%) and un-
likely to be clinically important.
Signiﬁcanttreatmenteffectsmayhave
been masked by our selection of subjects
with predominantly mild LVDD and sat-
isfactory control of BP, lipids, and glyce-
mia. Many were taking medications that
couldhaveaffectedcardiacfunction,such
as ACE inhibitors, angiotensin receptor
blockers, and statins. Fenoﬁbrate and
CoQ might have greater impact in pa-
tients with more advanced LVDD and
worseBPandmetaboliccontrol.Ischemic
heart disease was not formally excluded,
but no subjects had wall motion abnor-
malities on echocardiography.
Despite favorable effects on triglycer-
ides and apolipoproteins, fenoﬁbrate did
notraiseHDLcholesterolorlowerNEFAs
signiﬁcantly.However,mostsubjectshad
mild dyslipidemia. Greater treatment ef-
fects and clinical beneﬁt might be ex-
pected in patients with lower HDL
cholesterol (6). Whether higher-dose fe-
noﬁbrate and CoQ given for longer peri-
ods could improve LVDD needs to be
established.
Thestrengthsofourstudyincludethe
use of contemporary techniques (includ-
ing tissue Doppler imaging) and multiple
echocardiographic indexes to assess car-
diac function. Traditional diastolic func-
tion measures (indirect mitral inﬂow
indexes such as E/A, DT, and IVRT) may
be affected by volume loading and have
nonlinear associations with LVDD; our
primary end point, E, is less load depen-
dent. Measurement of PV ﬂow and Vp
yielded additional diastolic function in-
dexes, and we carefully selected subjects
for having LVDD using a comprehensive
classiﬁcation system. We did not observe
any treatment effect on this categorical
LVDDdeﬁnition,butourstudyhadinsuf-
ﬁcient power to test this.
Blood pressure
Clinical trials of fenoﬁbrate in type 2 dia-
betes have yielded inconsistent BP ﬁnd-
ings. In the FIELD study, there was a
placebo-adjusted 2 mmHg systolic and 1
mmHgdiastolicreductioninmedianCBP
(6), but in the smaller Diabetes Athero-
sclerosisInterventionStudy(DAIS),there
wasnosigniﬁcantchange(5).Bycontrast,
an uncontrolled short-term study in
healthyadultsshowedthatfenoﬁbratein-
creasedambulatorySBPby3mmHg(18).
Animal experiments suggest a role for
PPAR- in mediating hypertension and
atherosclerosis (19), but their relevance
to human disease is uncertain. Meta-
analyses suggest that CoQ supplementa-
tioninhypertensivepatientsreducesCBP
byupto10mmHgSBPand8mmHgDBP
(9), but its effect on ABP has not been
previously examined.
Our ﬁnding that fenoﬁbrate and CoQ
independently and interactively lowered
Table 4—Effect of interventions on ABP and HR
Placebo Fenoﬁbrate CoQ Combination
P for
interaction
Fenoﬁbrate
main effect P
CoQ main
effect P
n 15 15 10 14
24-h
SBP (mmHg)
Baseline 125.4  1.5 130.3  2.8 126.2  3.6 125.7  3.1
End 126.0  2.5 130.2  3.2 125.9  4.7 123.0  2.6 0.001 ————
DBP (mmHg)
Baseline 73.8  2.3 73.1  1.9 73.5  2.0 72.3  1.9
End 74.3  2.9 72.1  1.9 72.3  2.7 70.1  1.6 0.732 1.3  0.5 0.013 2.2  0.5  0.001
HR (bpm)
Baseline 73.9  2.8 72.3  2.7 70.4  2.5 73.3  2.8
End 74.5  2.5 70.2  2.9 72.7  2.3 70.9  2.4 0.859 3.3  0.5  0.001 0.2  0.5 0.716
Awake
SBP (mmHg) 130.3  1.6 134.5  2.8 130.8  2.9 130.1  3.3
Baseline 130.5  2.9 134.3  3.0 130.4  4.6 129.0  2.7 0.035 ————
End
DBP (mmHg) 77.9  2.5 76.2  1.7 77.3  1.8 76.2  2.1
Baseline 78.5  3.0 75.3  1.9 76.1  3.0 74.3  1.6 0.275 0.6  0.6 0.319 2.7  0.6  0.001
End
HR (bpm)
Baseline 77.0  3.1 75.8  3.1 73.2  2.9 76.2  3.2
End 77.5  2.6 72.6  3.3 75.8  2.6 74.9  2.7 0.285 3.0  0.7  0.001 0.6  0.6 0.305
Asleep
SBP (mmHg)
Baseline 114.6  2.0 120.6  3.4 116.4  6.3 117.0  3.3
End 116.5  2.6 120.0  3.7 117.9  5.5 111.4  2.9 0.002 ————
DBP (mmHg)
Baseline 65.1  2.2 65.8  2.2 64.9  3.2 64.6  1.8
End 65.8  2.6 64.9  2.0 66.7  3.1 61.4  1.8 0.392 2.6  0.9 0.005 1.3  0.9 0.139
HR (bpm)
Baseline 67.4  2.3 65.1  2.3 64.8  2.3 67.3  2.2
End 68.5  2.5 64.0  2.6 67.2  2.2 63.2  2.1 0.381 3.5  0.7  0.001 0.1  0.6 0.858
Data are means  SEM. Main effect vs. placebo, adjusted for baseline, study site, hour, change in weight, and antihypertensive medication use (mixed models).
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fects on endothelial dysfunction. Fenoﬁ-
brate’s hypotensive effect may reﬂect
increased endothelial NO bioavailability
and reduced endothelin-1 production.
CoQcouldimproveNObioavailabilityby
reducing oxidative stress and recoupling
NO synthase activity. However, fenoﬁ-
brateandCoQ’sinteractiveeffectsmaybe
mediated by non-NO mechanisms (11).
We previously showed that CoQ, but
not fenoﬁbrate, reduced CBP (11). In the
present study, we were able to demon-
strate independent and interactive effects
of both treatments on ABP, possibly be-
cause multiple measurements over 24 h
provide greater statistical power, even
with limited sample sizes. Fenoﬁbrate,
alone or combined with CoQ, had greater
effectsatnightperhapsbecauseBPissub-
ject to less variation during sleep. This
does not, however, explain CoQ’s greater
effect on daytime BP, which might be due
to interaction with factors such as con-
comitant morning medications.
In hypertensive type 2 diabetic pa-
tients, lowering CBP reduces macro- and
microvascular complications. However,
ABP, in particular nocturnal BP, predicts
cardiovascular risk better than CBP (20).
By lowering ABP, especially at night, fe-
noﬁbrate and CoQ may potentially im-
prove clinical outcomes in diabetes,
where concomitant hypertension aug-
ments risk. In the FIELD study, modest
lowering of CBP was not paralleled by re-
duction in coronary events, although sec-
ondary vascular outcomes were reduced
(6).Longertreatmentmayberequiredfor
BP reduction to improve LVDD (16), as
processes such as LV remodelling occur
over an extended period.
HR
HR may be an important therapeutic
target because it independently predicts
cardiovascular risk (21). In hypertri-
glyceridemic subjects, short-term bezaﬁ-
brate treatment reduced clinic HR by 3
bpm, (22), but no controlled studies have
examined ﬁbrate effects on ambulatory
HR. In our study, fenoﬁbrate lowered HR
throughout the 24-h period by 3 bpm,
which may translate to a 10–15% reduc-
tion in cardiovascular risk (21). The under-
lying mechanism is unclear. HR reduction
may reﬂect increased myocardial efﬁciency
and decreased oxygen demand related to
decreased lipid substrate supply (1). Other
possibilities include PPAR-–mediated ef-
fects on baroreceptor and cardiac pace-
maker sensitivity or sympathovagal
outﬂow.Indeed,PPAR-affectsorphannu-
clear receptor Rev-erb- expression (23),
which regulates clock genes mediating cir-
cadian hemodynamic and sympathoadre-
nal responses. NO also regulates cardiac
autonomic function, but whether fenoﬁ-
brate alters sympathovagal tone through
this mechanism merits investigation.
Although fenoﬁbrate and CoQ did
not improve diastolic function in type 2
diabeticpatientswithmildLVDDandsat-
isfactory BP and metabolic control, we
observed beneﬁcial hemodynamic effects
with no signiﬁcant adverse cardiac se-
quelae.Furtherstudiesarerequiredtoex-
plore the beneﬁts and risks of fenoﬁbrate
and CoQ in diabetic patients with more
severe LVDD and metabolic abnormali-
tiestreatedforlongerperiods.Combining
these treatments with agents such as
renin-angiotensin system inhibitors and
advanced glycation end-product cross-
link breakers should be investigated. Ulti-
mately,largerlong-termtrialsarerequired
to determine whether combining fenoﬁ-
brate with CoQ reduces clinical cardio-
vascular outcomes, such as heart failure,
in type 2 diabetes.
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